Characteristics of cases and controls selected from PCBaSe 3.0.

Characteristics of cases and controls selected from PCBaSe 3.0.</p

Odds ratios (OR) and 95% confidence intervals (CI) for PCa based on prescriptions of lower urinary-tract infection-related antibiotics.

<p>Odds ratios (OR) and 95% confidence intervals (CI) for PCa based on prescriptions of lower urinary-tract infection-related antibiotics.</p

PCa specific characteristics of cases selected from PCBaSe 3.0.

<p>PCa specific characteristics of cases selected from PCBaSe 3.0.</p

Odds ratios (OR) and 95% confidence intervals (CI) for PCa based on history of lower urinary-tract infection.

<p>Odds ratios (OR) and 95% confidence intervals (CI) for PCa based on history of lower urinary-tract infection.</p

Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival

Objectives: Randomised controlled trials (RCTs) have investigated the use of neoadjuvant chemotherapy (NAC) and its effect on survival patients with non-metastatic muscle-invasive bladder cancer (MIBC). However, these RCTs have limited external validity and generalisability and, therefore, the current study aims to use real world evidence in the form of observational data to identify the effect that NAC may have on survival, compared to the use of radical cystectomy (RC) alone. Materials and methods: The study cohort (consisting of 944 patients) was selected as a target trial from the Bladder Cancer Data Base Sweden (BladderBaSe). This study calculated 5-year survival and risk of bladder cancer (BC)-specific and overall death by Cox proportional hazard models for the study cohort and a propensity score (PS) matched cohort. Results: Those who had received NAC had higher 5-year survival proportions and decreased risk of both overall and BC specific death (HR = 0.71, 95% CI = 0.52–0.97 and HR = 0.67, 95% CI = 0.48–0.94), respectively, as compared to patients who did not receive NAC. The PS matched cohort showed similar estimates, but with larger statistical uncertainty (Overall death: HR = 0.76, 95% CI = 0.53–1.09 and BC-specific death: HR = 0.73, 95% CI = 0.50–1.07). Conclusion: Results from the current observational study found similar point estimates for 5-year survival and of relative risks as previous studies. However, the results based on real world evidence had larger statistical variability, resulting in a non-statistically significant effect of NAC on survival. Future studies with detailed validated data can be used to further investigate the effect of NAC in narrower patient groups.</p

Additional file 1 of The incidence and prevalence of upper tract urothelial carcinoma: a systematic review

Additional file 1. Search strategy

Additional file 2 of The incidence and prevalence of upper tract urothelial carcinoma: a systematic review

Additional file 2. Study descriptives sorted by population characteristics

Additional file 2: of Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study

List of conditions and medications included as exposures (DOCX 19 kb

Additional file 1: of Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study

Table S1. Adjusted Odds for association between AIMs exposure and PCa diagnosis in sensitivity analyses. Table S2. Adjusted Odds for association between AIMs exposure and PCa diagnosis in sensitivity analyses (DOCX 17 kb

sj-docx-1-uro-10.1177_20514158211065949 – Supplemental material for MRI-based nomogram for the prediction of prostate cancer diagnosis: A multi-centre validated patient–physician decision tool

Supplemental material, sj-docx-1-uro-10.1177_20514158211065949 for MRI-based nomogram for the prediction of prostate cancer diagnosis: A multi-centre validated patient–physician decision tool by Edwin M Chau, Beth Russell, Aida Santaolalla, Mieke Van Hemelrijck, Stuart McCracken, Toby Page, Sidath H Liyanage, Jonathan Aning, Vincent J Gnanapragasam and Peter Acher in Journal of Clinical Urology</p